These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

342 related items for PubMed ID: 28603207

  • 21. Subacute CNS Demyelination after Treatment with Nivolumab for Melanoma.
    Maurice C, Schneider R, Kiehl TR, Bavi P, Roehrl MH, Mason WP, Hogg D.
    Cancer Immunol Res; 2015 Dec; 3(12):1299-302. PubMed ID: 26419960
    [Abstract] [Full Text] [Related]

  • 22. Oral lichenoid reaction showing multiple ulcers associated with anti-programmed death cell receptor-1 treatment: A report of two cases and published work review.
    Obara K, Masuzawa M, Amoh Y.
    J Dermatol; 2018 May; 45(5):587-591. PubMed ID: 29352490
    [Abstract] [Full Text] [Related]

  • 23. Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy.
    Vivar KL, Deschaine M, Messina J, Divine JM, Rabionet A, Patel N, Harrington MA, Seminario-Vidal L.
    J Cutan Pathol; 2017 Apr; 44(4):381-384. PubMed ID: 28000240
    [Abstract] [Full Text] [Related]

  • 24. Immune-mediated thrombocytopenia and hypothyroidism in a lung cancer patient treated with nivolumab.
    Jotatsu T, Oda K, Yamaguchi Y, Noguchi S, Kawanami T, Kido T, Satoh M, Yatera K.
    Immunotherapy; 2018 Feb; 10(2):85-91. PubMed ID: 29260625
    [Abstract] [Full Text] [Related]

  • 25. Granulocyte colony-stimulating-factor-induced psoriasiform dermatitis resembles psoriasis with regard to abnormal cytokine expression and epidermal activation.
    Mössner R, Beckmann I, Hallermann C, Neumann C, Reich K.
    Exp Dermatol; 2004 Jun; 13(6):340-6. PubMed ID: 15186319
    [Abstract] [Full Text] [Related]

  • 26. RAPID EVOLUTION OF THYROID DYSFUNCTION IN PATIENTS TREATED WITH NIVOLUMAB.
    O'Malley G, Lee HJ, Parekh S, Galsky MD, Smith CB, Friedlander P, Yanagisawa RT, Gallagher EJ.
    Endocr Pract; 2017 Oct; 23(10):1223-1231. PubMed ID: 29045188
    [Abstract] [Full Text] [Related]

  • 27. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis.
    Bergqvist V, Hertervig E, Gedeon P, Kopljar M, Griph H, Kinhult S, Carneiro A, Marsal J.
    Cancer Immunol Immunother; 2017 May; 66(5):581-592. PubMed ID: 28204866
    [Abstract] [Full Text] [Related]

  • 28. Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease.
    Danlos FX, Voisin AL, Dyevre V, Michot JM, Routier E, Taillade L, Champiat S, Aspeslagh S, Haroche J, Albiges L, Massard C, Girard N, Dalle S, Besse B, Laghouati S, Soria JC, Mateus C, Robert C, Lanoy E, Marabelle A, Lambotte O.
    Eur J Cancer; 2018 Mar; 91():21-29. PubMed ID: 29331748
    [Abstract] [Full Text] [Related]

  • 29. Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer.
    Kawakami H, Tanizaki J, Tanaka K, Haratani K, Hayashi H, Takeda M, Kamata K, Takenaka M, Kimura M, Chikugo T, Sato T, Kudo M, Ito A, Nakagawa K.
    Invest New Drugs; 2017 Aug; 35(4):529-536. PubMed ID: 28317087
    [Abstract] [Full Text] [Related]

  • 30. Relapsed Myasthenia Gravis after Nivolumab Treatment.
    Mitsune A, Yanagisawa S, Fukuhara T, Miyauchi E, Morita M, Ono M, Tojo Y, Ichinose M.
    Intern Med; 2018 Jul 01; 57(13):1893-1897. PubMed ID: 29434145
    [Abstract] [Full Text] [Related]

  • 31. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
    Larkin J, Lao CD, Urba WJ, McDermott DF, Horak C, Jiang J, Wolchok JD.
    JAMA Oncol; 2015 Jul 01; 1(4):433-40. PubMed ID: 26181250
    [Abstract] [Full Text] [Related]

  • 32. [Clinical practice and mechanism of endocrinological adverse events associated with immune checkpoint inhibitors].
    Iwama S, Arima H.
    Nihon Rinsho Meneki Gakkai Kaishi; 2017 Jul 01; 40(2):90-94. PubMed ID: 28603206
    [Abstract] [Full Text] [Related]

  • 33. [Initially undetected de novo psoriasis triggered by nivolumab for metastatic base of the tongue carcinoma].
    Troyanova-Slavkova S, Eickenscheidt L, Dumann K, Kowalzick L.
    Hautarzt; 2018 Aug 01; 69(8):674-680. PubMed ID: 29330579
    [Abstract] [Full Text] [Related]

  • 34. Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: A case report.
    Uenami T, Hosono Y, Ishijima M, Kanazu M, Akazawa Y, Yano Y, Mori M, Yamaguchi T, Yokota S.
    Lung Cancer; 2017 Jul 01; 109():42-44. PubMed ID: 28577948
    [Abstract] [Full Text] [Related]

  • 35. A case of pure red cell aplasia during nivolumab therapy for cardiac metastatic melanoma.
    Yuki A, Takenouchi T, Takatsuka S, Ishiguro T.
    Melanoma Res; 2017 Dec 01; 27(6):635-637. PubMed ID: 28872489
    [Abstract] [Full Text] [Related]

  • 36. Activation of CD8 T cells accelerates anti-PD-1 antibody-induced psoriasis-like dermatitis through IL-6.
    Tanaka R, Ichimura Y, Kubota N, Saito A, Nakamura Y, Ishitsuka Y, Watanabe R, Fujisawa Y, Kanzaki M, Mizuno S, Takahashi S, Fujimoto M, Okiyama N.
    Commun Biol; 2020 Oct 15; 3(1):571. PubMed ID: 33060784
    [Abstract] [Full Text] [Related]

  • 37. Intracellular accumulation of PD-1 molecules in circulating T lymphocytes in advanced malignant melanoma: an implication for immune evasion mechanism.
    Takahashi R, Sato Y, Kimishima M, Shiohara T, Ohyama M.
    Int J Clin Oncol; 2020 Oct 15; 25(10):1861-1869. PubMed ID: 32656742
    [Abstract] [Full Text] [Related]

  • 38. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment.
    Tillack C, Ehmann LM, Friedrich M, Laubender RP, Papay P, Vogelsang H, Stallhofer J, Beigel F, Bedynek A, Wetzke M, Maier H, Koburger M, Wagner J, Glas J, Diegelmann J, Koglin S, Dombrowski Y, Schauber J, Wollenberg A, Brand S.
    Gut; 2014 Apr 15; 63(4):567-77. PubMed ID: 23468464
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.